Gilead Sciences, Inc. (NAS: GILD) Stock Analysis & Fundamentals

GILDGilead Sciences, Inc.

NAS · US · Healthcare · Drug Manufacturers - General · gilead.com

136.30USD+3.49%Mkt Cap: 169.23B $P/E: 18.541d ago

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, D…

Headline	Source	Time
Yesterday
Kalshi Allows Betting On Clinical Trials And FDA Drug Decisions Prediction market Kalshi is allowing users to bet on the outcomes of clinical trials and U.S. Food and Drug Adminis...	CryptoProwl	19h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.	Zacks	23h
Kalshi Will Offer Sports-Style Betting on Drug Trial Results (Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI CompanionCIA Says AI Drones Give Russian Troops Only 30 Minutes to LiveBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthOnePlus	Bloomberg	1d
This week
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity? Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually deserves a second look.	24/7 Wall St.	2d
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1 Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Gilead Sciences (NASDAQ:GILD) and the best and worst performers in the therapeutics industry.	StockStory	Jul 14
Own Regeneron For Biotech Growth? Incyte Is Making Its Case. For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.	Trefis	Jul 13
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.	Motley Fool	Jul 12
Older
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts	Zacks	Jul 10
2 Recession-Resistant Dividend Stocks to Buy and Hold	Motley Fool	Jul 10
Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?	Simply Wall St.	Jul 9
Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access	Simply Wall St.	Jul 9
Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative	Simply Wall St.	Jul 9
Morgan Stanley Keeps Buy Rating on Gilead (GILD)	Insider Monkey	Jul 8
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT Newswires	Jul 8
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says	MT Newswires	Jul 8
Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”	24/7 Wall St.	Jul 7
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?	Zacks	Jul 6
The Cancer Therapy Strategy VERAXA Is Betting the Company On	Exec Edge	Jul 6
Okta upgraded, Datadog downgraded: Wall Street's top analyst calls	The Fly	Jul 6
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More	24/7 Wall St.	Jul 6
Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?	Insider Monkey	Jul 5
The FDA Just Approved a KEYTRUDA Combination That Could Become the Standard First-Line Treatment for Aggressive Breast Cancer	Insider Monkey	Jul 1
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug	Zacks	Jul 1
Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial	Exec Edge	Jun 30
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?	Zacks	Jun 29
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC	Insider Monkey	Jun 28
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?	Simply Wall St.	Jun 27
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe	Simply Wall St.	Jun 27
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?	Zacks	Jun 26
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results	Insider Monkey	Jun 26
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know	Zacks	Jun 25
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use	Zacks	Jun 25
New Drugs Are Replacing Chemo for Aggressive Breast Cancer	The Wall Street Journal	Jun 24
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development	Exec Edge	Jun 24
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC	Zacks	Jun 24
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.	MarketBeat	Jun 23
Should You Buy Or Sell AbbVie Stock At $230?	Trefis	Jun 23
3 S&P 500 Stocks with Exciting Potential	StockStory	Jun 23
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing	Exec Edge	Jun 22
Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver?	Insider Monkey	Jun 22
Merck (MRK) Wins FDA Expansions, Posts HIV Data, And Ends Lung Cancer Trial	Simply Wall St.	Jun 22
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026	Exec Edge	Jun 18
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know	Zacks	Jun 18
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?	StockStory	Jun 18
Gilead Sciences (GILD) Donates Remdesivir to Uganda	Insider Monkey	Jun 17
1 Cash-Producing Stock Worth Investigating and 2 We Brush Off	StockStory	Jun 17
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK	Zacks	Jun 17
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention	Zacks	Jun 16
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know	Zacks	Jun 15
Regulatory Milestone Boosts Gilead’s Presence in Liver Disease Care	Insider Monkey	Jun 15

Industry Peers